Breast cancer cells harboring loss-of-function mutations in MAP2K4 (and MAP3K1) lack JNK-mediated activation of ErbB→CRAF→MEK1/2, and thus, are highly sensitive to MEKi35. This evidence concerns the gene MAP3K1 and breast carcinoma.